Product image of Kwikaton (Vildagliptin) supplied by GNH India

Kwikaton

Active Ingredient:
Vildagliptin
Origin:
EU

Kwikaton (Vildagliptin)

Vildagliptin, the active ingredient in Kwikaton, is a dipeptidyl peptidase‑4 (DPP‑4) inhibitor presented as an oral tablet for oral use. It is used to improve glycaemic control in adults with type 2 diabetes mellitus. GNH India supplies Kwikaton as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Stada Arzneimittel Ag

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Kwikaton (vildagliptin) acts on the incretin pathway to manage hyperglycaemia in type 2 diabetes.

  • Type 2 diabetes mellitus: lowers fasting and post‑prandial blood glucose levels.
  • HbA1c reduction: contributes to a measurable decrease in glycated haemoglobin.
  • Adjunct to diet and exercise: enhances the effect of lifestyle interventions when combined with other antidiabetic agents.

How It Works

  • Vildagliptin selectively inhibits the dipeptidyl peptidase‑4 enzyme, preventing the rapid degradation of endogenous incretin hormones (GLP‑1 and GIP). Elevated incretin levels stimulate glucose‑dependent insulin secretion and suppress glucagon release, thereby improving post‑prandial and fasting glycaemia without causing hypoglycaemia when used alone.

Side Effects

Common side effects are generally mild and transient.

Common Side Effects

  • Nausea: occasional mild stomach upset.
  • Headache: transient cranial discomfort.
  • Dizziness: occasional light‑headedness.
  • Upper respiratory tract infection: mild cold‑like symptoms.
  • Arthralgia: joint pain without swelling.
  • Hypoglycaemia (when combined with insulin or sulfonylureas): low blood sugar episodes.

Serious or Rare Side Effects

  • Pancreatitis: severe abdominal pain requiring immediate medical attention.
  • Severe allergic reactions: rash, swelling, or anaphylaxis.
  • Hepatic dysfunction: elevated liver enzymes.
  • Bullous pemphigoid: blistering skin disorder.
  • Stevens‑Johnson syndrome: severe skin and mucosal reactions.
  • Acute kidney injury: reduced renal function in susceptible patients.

Precautions & Warnings

Patients should be evaluated for specific risk factors before initiating therapy.

  • Renal impairment: assess kidney function and adjust dose if necessary.
  • Hepatic impairment: use with caution in patients with liver disease.
  • Elderly patients: monitor for hypoglycaemia, especially when combined with other agents.
  • Pregnancy and lactation: safety not established; avoid unless benefits outweigh risks.
  • Concomitant insulin or sulfonylureas: increased risk of hypoglycaemia; monitor glucose closely.
  • Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Avoid Interactions

Vildagliptin may interact with several drug classes, requiring clinical vigilance.

Major Interactions (Avoid)

  • Insulin: may cause severe hypoglycaemia.
  • Sulfonylureas (e.g., glipizide, glyburide): heightened risk of low blood glucose.

Moderate Interactions (Monitor Closely)

  • Diuretics (thiazides): may affect blood glucose control.
  • Rifampin: enzyme induction can reduce vildagliptin exposure.
  • Warfarin: potential alteration of INR; monitor coagulation parameters.
  • Digoxin: possible increase in serum levels; observe for toxicity.
  • Beta‑blockers: may mask hypoglycaemia symptoms; advise careful monitoring.

Frequently Asked Questions

Kwikaton contains vildagliptin, a DPP‑4 inhibitor prescribed to improve blood glucose control in adults with type 2 diabetes mellitus, usually as part of a comprehensive treatment plan that includes diet, exercise, and other antidiabetic agents.

Vildagliptin blocks the dipeptidyl peptidase‑4 enzyme, which normally degrades incretin hormones. By preserving incretins, it enhances glucose‑dependent insulin release and reduces glucagon secretion, leading to lower blood glucose levels after meals and during fasting.

The prescribed dose of Kwikaton is determined by the treating physician based on the patient’s glycaemic profile, renal function, and concomitant therapies. Patients should follow the exact dosing instructions provided by their healthcare professional.

Safety of vildagliptin in pregnancy and lactation has not been established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by a qualified healthcare provider.

To order Kwikaton, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and required import documentation.

Compared with sulfonylureas, vildagliptin has a lower intrinsic risk of hypoglycaemia when used alone. Unlike metformin, it does not cause gastrointestinal intolerance. It is often combined with other agents to achieve synergistic glucose‑lowering effects while maintaining a favourable safety profile.

Kwikaton tablets should be stored at ambient temperature, below 25 °C, in the original blister pack or container. Protect the product from moisture, heat, and direct sunlight to maintain potency throughout its shelf life.

Kwikaton is taken orally, usually once daily with or without food, as directed by the prescribing clinician. The tablet should be swallowed whole with water and not chewed or crushed unless specifically advised.

Serious risks include pancreatitis, severe allergic reactions such as anaphylaxis, and rare hepatic dysfunction. Patients should seek immediate medical attention for persistent abdominal pain, rash, or signs of liver injury while on therapy.

Kwikaton is contraindicated in patients with a known hypersensitivity to vildagliptin or any component of the formulation. It should also be avoided in individuals with severe renal impairment (eGFR <30 mL/min/1.73 m²) unless dose‑adjusted by a specialist.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Vildagliptin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT